E2F Transcription Factors: Activators, Repressors and Cancer
E2F transcription factors are the output of the RB pathway: they switch on the genes needed for DNA replication and cell division. The family contains both activators and repressors, and their combined activity is elevated in almost every cancer as a downstream consequence of RB-pathway disruption.
Quick Answer
E2F transcription factors are the output of the RB pathway: they switch on the genes needed for DNA replication and cell division. The family contains both activators and repressors, and their combined activity is elevated in almost every cancer as a downstream consequence of RB-pathway disruption.
An Eight-Member Family
The E2F family comprises E2F1 to E2F8. E2F1, E2F2 and E2F3a act mainly as transcriptional activators; E2F3b through E2F6 tend to repress; and the atypical members E2F7 and E2F8 repress independently of a DP partner and of RB.
This division lets the pathway both switch genes on at the right time and switch them off again once S phase is complete.
Control by RB Pocket Proteins
The three pocket proteins RB, p107 and p130 bind different E2Fs and recruit chromatin-modifying complexes to keep target genes silent during G0 and early G1.
CDK-mediated phosphorylation of the pocket proteins releases the activator E2Fs at the G1/S transition. Loss of RB, or forced CDK activity, produces constitutive activator-E2F function.
What Activator E2Fs Switch On
Activator E2F targets include cyclin E, CDC6, the MCM helicase subunits, thymidine kinase, dihydrofolate reductase and ribonucleotide reductase, essentially the toolkit for copying DNA.
Overexpression of these targets sustains proliferation and can also increase replication stress, linking E2F hyperactivity to genomic instability.
E2F1 and Cell Death
E2F1 is not purely pro-proliferative. When strongly or aberrantly activated it also induces apoptotic genes and stabilises p53 through ARF, providing a fail-safe against runaway cycling.
Tumours that keep high E2F1 activity generally also carry lesions that blunt this apoptotic output, such as p53 pathway loss.
E2F in Tumour Data and Therapy
Pan-cancer analyses find E2F target-gene signatures elevated across most tumour types, often correlating with proliferation rate and, in some cancers, with prognosis.
There is no approved drug that targets E2F directly. CDK4/6 and CDK2 inhibitors act upstream, and E2F signatures are used in research as readouts of pathway activity rather than as standalone clinical tests.
Key Takeaways
- ·E2F1 to E2F8 include activators, repressors and RB-independent atypical members.
- ·RB, p107 and p130 hold E2F targets off until CDK phosphorylation releases them.
- ·Activator E2Fs drive DNA-replication genes; E2F1 can also trigger apoptosis.
- ·Raised E2F activity is a near-universal downstream feature of RB-pathway disruption and is a research readout, not a clinical assay.
Put these genes in pathway context
Frequently asked questions
What is the key idea in E2F Transcription Factors: Activators, Repressors and Cancer?
E2F transcription factors are the output of the RB pathway: they switch on the genes needed for DNA replication and cell division. The family contains both activators and repressors, and their combined activity is elevated in almost every cancer as a downstream consequence of RB-pathway disruption.
What should be kept with the result or mechanism?
RB, p107 and p130 hold E2F targets off until CDK phosphorylation releases them. Activator E2Fs drive DNA-replication genes; E2F1 can also trigger apoptosis. Raised E2F activity is a near-universal downstream feature of RB-pathway disruption and is a research readout, not a clinical assay.
References
- 1The broken cycle: E2F dysfunction in cancer. Nature Reviews Cancer, 2019. PubMed
- 2Integrated analysis of the E2F transcription factors across cancer types. Oncology Reports, 2020. PubMed
- 3The retinoblastoma protein and cell-cycle control. Nature Reviews Cancer, 2012. PubMed
- 4Human papillomavirus oncoproteins: pathways to transformation. Nature Reviews Cancer, 2010. PubMed
Continue Reading
The Cyclin D-CDK4/6-RB Axis: How Cells Enter the Division Cycle
3 min read
The G1/S Restriction Point: Where a Cell Commits to Dividing
3 min read
Cell-Cycle Checkpoints Explained: G1/S, Intra-S, G2/M and Mitosis
4 min read
RB1 Loss in Cancer: Cell-Cycle Biology and Testing
2 min read
CCNE1 Amplification and Cyclin E: Biology and Testing Context
3 min read
CDKN2A and MTAP Co-Deletion: Understanding the 9p21 Region
2 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
RB1 has 150+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.